Current Drug Delivery Strategies to Design Orally Dissolving Formulations to Target Tuberculosis: A Futuristic Review

Pinky Chowrasia, Mohini Singh, Bani Kumar Jana, Pankaj Lochan Bora, Ranjit Kumar Mahato, Rikynjai Kharbithai, Niva Rani Gogoi, Tumpa Sarkar, Paulomi Pal, Bhaskar Mazumder
{"title":"Current Drug Delivery Strategies to Design Orally Dissolving Formulations to Target Tuberculosis: A Futuristic Review","authors":"Pinky Chowrasia, Mohini Singh, Bani Kumar Jana, Pankaj Lochan Bora, Ranjit Kumar Mahato, Rikynjai Kharbithai, Niva Rani Gogoi, Tumpa Sarkar, Paulomi Pal, Bhaskar Mazumder","doi":"10.2174/0122103031267044231031044456","DOIUrl":null,"url":null,"abstract":"\n\nAll the standard anti-tubercular drugs, well established as standard therapy, are prefer-entially available in formulations compliant with the young adult population. However, their use in the paediatric and geriatric populations is confronted with issues, such as a high likelihood of incorrect dose administration due to practices like dosage form fracture and splitting. This may lead to drug resistance due to misuse and in-accurate dosage administration, the most dreaded and difficult-to-treat stage of tuberculosis.\nPoor patient compliance and adherence are major issues with the conventional line of therapy. This burden may be more significant in resource-constrained settings, necessitating the creation of simple formulations that are both geriatric and child-friendly. An extensive literature survey has been conducted in this study using databases of Google Scholar, PubMed, and Research Gate, with a focus on specific research works on oro-dispersible films, tablets, and wafer technology loaded with anti-tuberculosis drugs from 2022 to 2010.\nMouth dissolving formulation technology is a very novel approach in the arena of tuberculosis therapy. This may pave the way for future researchers to develop different mouth dissolving for-mulations to treat both pulmonary and extra-tuberculosis. This review paper has summarized all the formulation approaches alongside the present state of the art in tuberculosis therapy using mouth dissolving formulations.\n","PeriodicalId":507230,"journal":{"name":"Drug Delivery Letters","volume":"5 5","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Delivery Letters","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0122103031267044231031044456","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

All the standard anti-tubercular drugs, well established as standard therapy, are prefer-entially available in formulations compliant with the young adult population. However, their use in the paediatric and geriatric populations is confronted with issues, such as a high likelihood of incorrect dose administration due to practices like dosage form fracture and splitting. This may lead to drug resistance due to misuse and in-accurate dosage administration, the most dreaded and difficult-to-treat stage of tuberculosis. Poor patient compliance and adherence are major issues with the conventional line of therapy. This burden may be more significant in resource-constrained settings, necessitating the creation of simple formulations that are both geriatric and child-friendly. An extensive literature survey has been conducted in this study using databases of Google Scholar, PubMed, and Research Gate, with a focus on specific research works on oro-dispersible films, tablets, and wafer technology loaded with anti-tuberculosis drugs from 2022 to 2010. Mouth dissolving formulation technology is a very novel approach in the arena of tuberculosis therapy. This may pave the way for future researchers to develop different mouth dissolving for-mulations to treat both pulmonary and extra-tuberculosis. This review paper has summarized all the formulation approaches alongside the present state of the art in tuberculosis therapy using mouth dissolving formulations.
设计针对结核病的口服溶解制剂的当前给药策略:展望未来
所有标准抗结核药物都是公认的标准疗法,其配方最好符合年轻成年人的需求。然而,在儿科和老年科人群中使用这些药物却面临着一些问题,例如由于剂型断裂和拆分等做法,给药剂量不正确的可能性很高。患者依从性和坚持性差是传统疗法的主要问题。在资源有限的环境中,这种负担可能会更加沉重,因此有必要创造出既适合老年人又适合儿童的简易制剂。本研究利用谷歌学术、PubMed 和 Research Gate 等数据库进行了广泛的文献调查,重点关注 2022 年至 2010 年期间有关口腔分散薄膜、片剂和晶片技术的具体研究成果。口腔溶解制剂技术在结核病治疗领域是一种非常新颖的方法,它可以为未来的研究人员开发不同的口腔溶解制剂来治疗肺结核和肺结核以外的疾病铺平道路。本综述总结了所有制剂方法,以及目前使用口腔溶解制剂治疗结核病的技术水平。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信